Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy

David M. Goldenberg, Robert M. Sharkey, Giovanni Paganelli, Jacques Barbet, Jean François Chatal

Research output: Contribution to journalArticle

271 Citations (Scopus)

Abstract

This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.

Original languageEnglish
Pages (from-to)823-834
Number of pages12
JournalJournal of Clinical Oncology
Volume24
Issue number5
DOIs
Publication statusPublished - Feb 10 2006

Fingerprint

Radioimmunodetection
Radioimmunotherapy
Radioisotopes
Antibodies
Neoplasms
Bispecific Antibodies
Neoplasm Antibodies
Streptavidin
Haptens
Carcinoembryonic Antigen
Small Cell Lung Carcinoma
Therapeutics
Biotin
Glioma
Thyroid Gland

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. / Goldenberg, David M.; Sharkey, Robert M.; Paganelli, Giovanni; Barbet, Jacques; Chatal, Jean François.

In: Journal of Clinical Oncology, Vol. 24, No. 5, 10.02.2006, p. 823-834.

Research output: Contribution to journalArticle

Goldenberg, David M. ; Sharkey, Robert M. ; Paganelli, Giovanni ; Barbet, Jacques ; Chatal, Jean François. / Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 5. pp. 823-834.
@article{88e4a5b3bbed4f2f9663c814692fdf8c,
title = "Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy",
abstract = "This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.",
author = "Goldenberg, {David M.} and Sharkey, {Robert M.} and Giovanni Paganelli and Jacques Barbet and Chatal, {Jean Fran{\cc}ois}",
year = "2006",
month = "2",
day = "10",
doi = "10.1200/JCO.2005.03.8471",
language = "English",
volume = "24",
pages = "823--834",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy

AU - Goldenberg, David M.

AU - Sharkey, Robert M.

AU - Paganelli, Giovanni

AU - Barbet, Jacques

AU - Chatal, Jean François

PY - 2006/2/10

Y1 - 2006/2/10

N2 - This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.

AB - This article reviews the methods of pretargeting, which involve separating the targeting antibody from the subsequent delivery of an imaging or therapeutic agent that binds to the tumor-localized antibody. This provides enhanced tumor:background ratios and the delivery of a higher therapeutic dose than when antibodies are directly conjugated with radionuclides, as currently practiced in cancer radioimmunotherapy. We describe initial promising clinical results using streptavidin-antibody constructs with biotin-radionuclide conjugates in the treatment of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and small-cell lung cancers.

UR - http://www.scopus.com/inward/record.url?scp=33644869654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644869654&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.8471

DO - 10.1200/JCO.2005.03.8471

M3 - Article

VL - 24

SP - 823

EP - 834

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -